Eric Burak
Chief Tech/Sci/R&D Officer at FUSN PHAR
Net worth: 823 686 $ as of 29/04/2024
Network origin in Eric Burak first degree
Entity | Entity type | Industry | |
---|---|---|---|
28
| Public Company | Pharmaceuticals: Major | 28 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Eric Burak via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Massachusetts Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member Chairman | |
Yale University | College/University | Graduate Degree Doctorate Degree | |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Pharmaceuticals: Major | Director/Board Member Founder | |
IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
McMaster University | College/University | Undergraduate Degree Corporate Officer/Principal | |
Aptalis Pharma LLC
Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
OTONOMY | Biotechnology | Director/Board Member Director/Board Member | |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Chief Executive Officer Chief Operating Officer | |
GENOCEA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
ENDOCYTE, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
The University of Colorado | College/University | Corporate Officer/Principal Doctorate Degree | |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Kernel Management Partners Ltd.
Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Investment Managers | Private Equity Investor | |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
2941881 Canada, Inc.
2941881 Canada, Inc. Medical SpecialtiesHealth Technology 2941881 Canada, Inc. manufactures and supplies pelvic health and gastrointestinal equipment and consumables. The company was founded by Raymond George Yves Laborie in 1967 and is headquartered in Mississauga, Canada. | Medical Specialties | Director/Board Member | |
Aerogen Ltd.
Aerogen Ltd. Medical SpecialtiesHealth Technology Aerogen Ltd. develops and manufactures aerosol products. It offers Aerogen Solo, Aerogen Ultra, Aerogen Pro, Pro-X controller and USB controller. The company was founded by John S. Power in 1997 and is headquartered in Galway, Ireland. | Medical Specialties | Director/Board Member | |
Multiple Myeloma Canada
Multiple Myeloma Canada Miscellaneous Commercial ServicesCommercial Services Multiple Myeloma Canada engages in the clinical research. It focuses on myeloma, a cancer of the plasma cells found in the bone marrow. The company was founded by Aldo Del Col in 2005 and is headquartered in Dorval, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member | |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
XENON PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Crescent Diagnostics Ltd.
Crescent Diagnostics Ltd. Medical/Nursing ServicesHealth Services Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Director of Finance/CFO | |
ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Director/Board Member | |
Aptalis Holdings, Inc.
Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Holdings Inc. operates as a holding company that develops, manufactures, licenses, markets and distributes therapies for unmet medical needs. It includes cystic fibrosis and gastrointestinal disorders through its subsidiaries. It also formulates and clinically develops enhanced pharmaceutical, biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking and orally disintegration tablet formulations. The company was founded on January 10, 2008 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Director of Finance/CFO | |
Concordia University | College/University | Undergraduate Degree | |
Mallinckrodt Medical, Inc.
Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | Medical Specialties | Director of Finance/CFO | |
Biosensia Ltd.
Biosensia Ltd. Packaged SoftwareTechnology Services Biosensia Ltd. develops multiplexing point of care in vitro diagnostics platform. It offers RapiPlex, a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results. The company was founded by Gareth Redmond and Gabriel Crean in 2009 and is headquartered in Dublin, Ireland. | Packaged Software | Director/Board Member | |
PrecisionBiotics Group Ltd.
PrecisionBiotics Group Ltd. Pharmaceuticals: GenericHealth Technology PrecisionBiotics Group Ltd. operates as a healthcare company. It focuses on isolation, characterization, clinical evaluation, and formulation of unique bacterial strain and actives for inflammatory and infectious conditions. The company was founded by Barry Kiely in 1999 and is headquartered In Cork, Ireland. | Pharmaceuticals: Generic | Director/Board Member | |
IMMUNOGEN, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Investment Managers | Private Equity Investor | |
ESTEE LAUDER | Household/Personal Care | Corporate Officer/Principal | |
Medicines & Healthcare Products Regulatory Agency | General Government | Corporate Officer/Principal | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Veryan Medical Ltd.
Veryan Medical Ltd. BiotechnologyHealth Technology Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
University of London | College/University | Graduate Degree |
Statistics
International
United States | 21 |
Canada | 12 |
United Kingdom | 9 |
Ireland | 8 |
France | 3 |
Sectoral
Health Technology | 34 |
Consumer Services | 7 |
Finance | 5 |
Commercial Services | 4 |
Health Services | 2 |
Operational
Director/Board Member | 207 |
Corporate Officer/Principal | 76 |
Independent Dir/Board Member | 51 |
Undergraduate Degree | 21 |
Doctorate Degree | 16 |
Most connected contacts
Insiders | |
---|---|
Chau Khuong | 38 |
Johan Rutger Christenson | 35 |
Heather Elizabeth Preston | 34 |
Asish Xavier | 33 |
Terry Gould | 26 |
Pablo Cagnoni | 24 |
Barbara Duncan | 22 |
Alan William O'Connell | 19 |
David Meek | 19 |
Damian Lamb | 14 |
Steven Gannon | 14 |
Jeremy Bender | 12 |
Donald Bergstrom | 9 |
John Crowley | 9 |
Paul Graham McCracken | 9 |
- Stock Market
- Insiders
- Eric Burak
- Company connections